Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Feb;114(4):837–845. doi: 10.1111/j.1476-5381.1995.tb13280.x

The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.

R Alemany 1, G Olmos 1, J A García-Sevilla 1
PMCID: PMC1510217  PMID: 7773544

Abstract

1. The binding of [3H]-idazoxan in the presence of 10(-6) M (-)-adrenaline was used to quantitate I2 imidazoline-preferring receptors in the rat brain and liver after chronic treatment with various irreversible and reversible monoamine oxidase (MAO) inhibitors. 2. Chronic treatment (7-14 days) with the irreversible MAO inhibitors, phenelzine (1-20 mg kg-1, i.p.), isocarboxazid (10 mg kg-1, i.p.), clorgyline (3 mg kg-1, i.p.) and tranylcypromine (10 mg kg-1, i.p.) markedly decreased (21-71%) the density of I2 imidazoline-preferring receptors in the rat brain and liver. In contrast, chronic treatment (7 days) with the reversible MAO-A inhibitors, moclobemide (1 and 10 mg kg-1, i.p.) or chlordimeform (10 mg kg-1, i.p.) or with the reversible MAO-B inhibitor Ro 16-6491 (1 and 10 mg kg-1, i.p.) did not alter the density of I2 imidazoline-preferring receptors in the rat brain and liver; except for the higher dose of Ro 16-6491 which only decreased the density of these putative receptors in the liver (38%). 3. In vitro, phenelzine, clorgyline, 3-phenylpropargylamine, tranylcypromine and chlordimeform displaced the binding of [3H]-idazoxan to brain and liver I2 imidazoline-preferring receptors from two distinct binding sites. Phenelzine, 3-phenylpropargylamine and tranylcypromine displayed moderate affinity (KiH = 0.3-6 microM) for brain and liver I2 imidazoline-preferring receptors; whereas chlordimeform displayed high affinity (KiH = 6 nM) for these receptors in the two tissues studied, Clorgyline displayed very high affinity for rat brain (KiH = 40 pM) but not for rat liver I2 imidazoline-preferring receptors (KiH = 169 nM).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
837

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allard P., Marcusson J. O., Ross S. B. [3H]GBR-12935 binding to cytochrome P450 in the human brain. J Neurochem. 1994 Jan;62(1):342–348. doi: 10.1046/j.1471-4159.1994.62010342.x. [DOI] [PubMed] [Google Scholar]
  2. Atlas D. Clonidine-displacing substance (CDS) and its putative imidazoline receptor. New leads for further divergence of alpha 2-adrenergic receptor activity. Biochem Pharmacol. 1991 Jun 1;41(11):1541–1549. doi: 10.1016/0006-2952(91)90152-u. [DOI] [PubMed] [Google Scholar]
  3. Bach A. W., Lan N. C., Johnson D. L., Abell C. W., Bembenek M. E., Kwan S. W., Seeburg P. H., Shih J. C. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4934–4938. doi: 10.1073/pnas.85.13.4934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baker G. B., Coutts R. T., McKenna K. F., Sherry-McKenna R. L. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatry Neurosci. 1992 Nov;17(5):206–214. [PMC free article] [PubMed] [Google Scholar]
  5. Bergh A. F., Strobel H. W. Reconstitution of the brain mixed function oxidase system: purification of NADPH-cytochrome P450 reductase and partial purification of cytochrome P450 from whole rat brain. J Neurochem. 1992 Aug;59(2):575–581. doi: 10.1111/j.1471-4159.1992.tb09408.x. [DOI] [PubMed] [Google Scholar]
  6. Bruns R. F., Lawson-Wendling K., Pugsley T. A. A rapid filtration assay for soluble receptors using polyethylenimine-treated filters. Anal Biochem. 1983 Jul 1;132(1):74–81. doi: 10.1016/0003-2697(83)90427-x. [DOI] [PubMed] [Google Scholar]
  7. Chen K., Wu H. F., Shih J. C. The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical. J Neurochem. 1993 Jul;61(1):187–190. doi: 10.1111/j.1471-4159.1993.tb03554.x. [DOI] [PubMed] [Google Scholar]
  8. Cresteil T., Beaune P., Celier C., Leroux J. P., Guengerich F. P. Cytochrome P-450 isoenzyme content and monooxygenase activities in rat liver: effect of ontogenesis and pretreatment by phenobarbital and 3-methylcholanthrene. J Pharmacol Exp Ther. 1986 Jan;236(1):269–276. [PubMed] [Google Scholar]
  9. De Vos H., Bricca G., De Keyser J., De Backer J. P., Bousquet P., Vauquelin G. Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system. Neuroscience. 1994 Apr;59(3):589–598. doi: 10.1016/0306-4522(94)90179-1. [DOI] [PubMed] [Google Scholar]
  10. Dupont H., Davies D. S., Strolin-Benedetti M. Inhibition of cytochrome P-450-dependent oxidation reactions by MAO inhibitors in rat liver microsomes. Biochem Pharmacol. 1987 May 15;36(10):1651–1657. doi: 10.1016/0006-2952(87)90050-5. [DOI] [PubMed] [Google Scholar]
  11. Escribá P. V., Sastre M., Wang H., Regunathan S., Reis D. J., García-Sevilla J. A. Immunodetection of putative imidazoline receptor proteins in the human and rat brain and other tissues. Neurosci Lett. 1994 Aug 29;178(1):81–84. doi: 10.1016/0304-3940(94)90295-x. [DOI] [PubMed] [Google Scholar]
  12. Giralt M. T., García-Sevilla J. A. Acute and long-term regulation of brain alpha 2-adrenoceptors after manipulation of noradrenergic transmission in the rat. Eur J Pharmacol. 1989 May 30;164(3):455–466. doi: 10.1016/0014-2999(89)90253-7. [DOI] [PubMed] [Google Scholar]
  13. Hieble J. P., Ruffolo R. R., Jr Imidazoline receptors: historical perspective. Fundam Clin Pharmacol. 1992;6 (Suppl 1):7S–13S. doi: 10.1111/j.1472-8206.1992.tb00136.x. [DOI] [PubMed] [Google Scholar]
  14. Hollingworth R. M., Leister J., Ghali G. Mode of action of formamidine pesticides: an evaluation of monoamine oxidase as the target. Chem Biol Interact. 1979 Jan;24(1):35–49. doi: 10.1016/0009-2797(79)90101-7. [DOI] [PubMed] [Google Scholar]
  15. Jonen H. G., Werringloer J., Prough R. A., Estabrook R. W. The reaction of phenylhydrazine with microsomal cytochrome P-450. Catalysis of heme modification. J Biol Chem. 1982 Apr 25;257(8):4404–4411. [PubMed] [Google Scholar]
  16. Kilpatrick A. T., Brown C. C., Mackinnon A. C. Non-alpha 2-adrenoceptor idazoxan binding sites; a new target for drug development. Biochem Soc Trans. 1992 Feb;20(1):113–118. doi: 10.1042/bst0200113. [DOI] [PubMed] [Google Scholar]
  17. Koop D. R., Crump B. L., Nordblom G. D., Coon M. J. Immunochemical evidence for induction of the alcohol-oxidizing cytochrome P-450 of rabbit liver microsomes by diverse agents: ethanol, imidazole, trichloroethylene, acetone, pyrazole, and isoniazid. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4065–4069. doi: 10.1073/pnas.82.12.4065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  19. Li G., Regunathan S., Barrow C. J., Eshraghi J., Cooper R., Reis D. J. Agmatine: an endogenous clonidine-displacing substance in the brain. Science. 1994 Feb 18;263(5149):966–969. doi: 10.1126/science.7906055. [DOI] [PubMed] [Google Scholar]
  20. Limon I., Coupry I., Lanier S. M., Parini A. Purification and characterization of mitochondrial imidazoline-guanidinium receptive site from rabbit kidney. J Biol Chem. 1992 Oct 25;267(30):21645–21649. [PubMed] [Google Scholar]
  21. McManus D. J., Mousseau D. D., Paetsch P. R., Wishart T. B., Greenshaw A. J. Beta-adrenoceptors and antidepressants: possible 2-phenylethylamine mediation of chronic phenelzine effects. Biol Psychiatry. 1991 Dec 1;30(11):1122–1130. doi: 10.1016/0006-3223(91)90182-l. [DOI] [PubMed] [Google Scholar]
  22. McPherson G. A. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods. 1985 Nov;14(3):213–228. doi: 10.1016/0160-5402(85)90034-8. [DOI] [PubMed] [Google Scholar]
  23. Meana J. J., Barturen F., Martin I., García-Sevilla J. A. Evidence of increased non-adrenoceptor [3H]idazoxan binding sites in the frontal cortex of depressed suicide victims. Biol Psychiatry. 1993 Oct 1;34(7):498–501. doi: 10.1016/0006-3223(93)90243-7. [DOI] [PubMed] [Google Scholar]
  24. Michel M. C., Ernsberger P. Keeping an eye on the I site: imidazoline-preferring receptors. Trends Pharmacol Sci. 1992 Oct;13(10):369–370. [PubMed] [Google Scholar]
  25. Michel M. C., Insel P. A. Are there multiple imidazoline binding sites? Trends Pharmacol Sci. 1989 Sep;10(9):342–344. doi: 10.1016/0165-6147(89)90002-3. [DOI] [PubMed] [Google Scholar]
  26. Miralles A., Olmos G., Sastre M., Barturen F., Martin I., Garcia-Sevilla J. A. Discrimination and pharmacological characterization of I2-imidazoline sites with [3H]idazoxan and alpha-2 adrenoceptors with [3H]RX821002 (2-methoxy idazoxan) in the human and rat brains. J Pharmacol Exp Ther. 1993 Mar;264(3):1187–1197. [PubMed] [Google Scholar]
  27. Miralles A., Ribas C., Olmos G., García-Sevilla J. A. Differential effects of the alkylating agent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on brain alpha 2-adrenoceptors and I2-imidazoline sites in vitro and in vivo. J Neurochem. 1993 Nov;61(5):1602–1610. doi: 10.1111/j.1471-4159.1993.tb09793.x. [DOI] [PubMed] [Google Scholar]
  28. Mousseau D. D., McManus D. J., Baker G. B., Juorio A. V., Dewhurst W. G., Greenshaw A. J. Effects of age and of chronic antidepressant treatment on [3H]tryptamine and [3H]dihydroalprenolol binding to rat cortical membranes. Cell Mol Neurobiol. 1993 Feb;13(1):3–13. doi: 10.1007/BF00712985. [DOI] [PubMed] [Google Scholar]
  29. Muakkassah S. F., Yang W. C. Mechanism of the inhibitory action of phenelzine on microsomal drug metabolism. J Pharmacol Exp Ther. 1981 Oct;219(1):147–155. [PubMed] [Google Scholar]
  30. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  31. Murray M., Reidy G. F. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev. 1990 Jun;42(2):85–101. [PubMed] [Google Scholar]
  32. Olmos G., Alemany R., Escriba P. V., García-Sevilla J. A. The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain. Br J Pharmacol. 1994 Apr;111(4):997–1002. doi: 10.1111/j.1476-5381.1994.tb14842.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Olmos G., Gabilondo A. M., Miralles A., Escriba P. V., García-Sevilla J. A. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain. Br J Pharmacol. 1993 Mar;108(3):597–603. doi: 10.1111/j.1476-5381.1993.tb12848.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Olmos G., Miralles A., Barturen F., Garcia-Sevilla J. A. Characterization of brain imidazoline receptors in normotensive and hypertensive rats: differential regulation by chronic imidazoline drug treatment. J Pharmacol Exp Ther. 1992 Mar;260(3):1000–1007. [PubMed] [Google Scholar]
  35. Paetsch P. R., Baker G. B., Greenshaw A. J. Induction of functional down-regulation of beta-adrenoceptors in rats by 2-phenylethylamine. J Pharm Sci. 1993 Jan;82(1):22–24. doi: 10.1002/jps.2600820105. [DOI] [PubMed] [Google Scholar]
  36. Piletz J. E., Halaris A., Saran A., Marler M. R. Desipramine lowers tritiated para-aminoclonidine binding in platelets of depressed patients. Arch Gen Psychiatry. 1991 Sep;48(9):813–820. doi: 10.1001/archpsyc.1991.01810330037006. [DOI] [PubMed] [Google Scholar]
  37. Piletz J. E., Halaris A., Saran A., Marler M. Elevated 3H-para-aminoclonidine binding to platelet purified plasma membranes from depressed patients. Neuropsychopharmacology. 1990 Jun;3(3):201–210. [PubMed] [Google Scholar]
  38. Renouard A., Widdowson P. S., Cordi A. [3H]-idazoxan binding to rabbit cerebral cortex recognises multiple imidazoline I2-type receptors: pharmacological characterization and relationship to monoamine oxidase. Br J Pharmacol. 1993 Jul;109(3):625–631. doi: 10.1111/j.1476-5381.1993.tb13618.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Sastre M., García-Sevilla J. A. Opposite age-dependent changes of alpha 2A-adrenoceptors and nonadrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) in the human brain: strong correlation of I2 with monoamine oxidase-B sites. J Neurochem. 1993 Sep;61(3):881–889. doi: 10.1111/j.1471-4159.1993.tb03599.x. [DOI] [PubMed] [Google Scholar]
  40. Tesson F., Parini A. Identification of an imidazoline-guanidinium receptive site in mitochondria from rabbit cerebral cortex. Eur J Pharmacol. 1991 Sep 12;208(1):81–83. doi: 10.1016/0922-4106(91)90055-m. [DOI] [PubMed] [Google Scholar]
  41. Tesson F., Prip-Buus C., Lemoine A., Pegorier J. P., Parini A. Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. Major localization to the mitochondrial outer membrane. J Biol Chem. 1991 Jan 5;266(1):155–160. [PubMed] [Google Scholar]
  42. Walther B., Ghersi-Egea J. F., Minn A., Siest G. Subcellular distribution of cytochrome P-450 in the brain. Brain Res. 1986 Jun 11;375(2):338–344. doi: 10.1016/0006-8993(86)90754-7. [DOI] [PubMed] [Google Scholar]
  43. Wang H., Regunathan S., Meeley M. P., Reis D. J. Isolation and characterization of imidazoline receptor protein from bovine adrenal chromaffin cells. Mol Pharmacol. 1992 Nov;42(5):792–801. [PubMed] [Google Scholar]
  44. Wang H., Regunathan S., Ruggiero D. A., Reis D. J. Production and characterization of antibodies specific for the imidazoline receptor protein. Mol Pharmacol. 1993 Apr;43(4):509–515. [PubMed] [Google Scholar]
  45. Warner M., Köhler C., Hansson T., Gustafsson J. A. Regional distribution of cytochrome P-450 in the rat brain: spectral quantitation and contribution of P-450b,e, and P-450c,d. J Neurochem. 1988 Apr;50(4):1057–1065. doi: 10.1111/j.1471-4159.1988.tb10573.x. [DOI] [PubMed] [Google Scholar]
  46. Yoshida Y., Aoyama Y. Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes. Biochem Pharmacol. 1987 Jan 15;36(2):229–235. doi: 10.1016/0006-2952(87)90694-0. [DOI] [PubMed] [Google Scholar]
  47. Zonnenchein R., Diamant S., Atlas D. Imidazoline receptors in rat liver cells: a novel receptor or a subtype of alpha 2-adrenoceptors? Eur J Pharmacol. 1990 Nov 6;190(1-2):203–215. doi: 10.1016/0014-2999(90)94127-j. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES